• Mashup Score: 0
    Fitusiran in haemophilia: a breakthrough drug with many unknowns - 1 year(s) ago

    Haemophilia A, defined by factor VIII (FVIII) deficiency, and haemophilia B, defined by factor IX (FIX) deficiency, are X chromosome linked diseases characterised by reduced thrombin generation and bleeding symptoms.1 Prophylaxis with replacement FVIII and FIX is considered the gold standard in haemophilia treatment. Over the past two decades, the treatment landscape in haemophilia has changed…

    Source: The Lancet
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetHaem
      TheLancetHaem

      "Fitusiran might be the first prophylactic option for people with haemophilia B and perhaps an alternative approach... in haemophilia A" Comment @TheLancet by @flora_peyvandi, Isabella Garagiola & Maria Abbattista #bleedingdisorders #hemophilia https://t.co/ic1QgkpCt2

  • Mashup Score: 0
    Fitusiran prophylaxis in severe haemophilia without inhibitors - 1 year(s) ago

    Haemophilia is a congenital X-linked bleeding disorder caused by deficiency of coagulation factors VIII (haemophilia A) or IX (haemophilia B). Recurrent joint bleeding, leading to the development of arthropathy, is the hallmark of haemophilia and is more pronounced in people with moderate to severe forms of the disease (<1–5% of normal factor VIII or IX concentrations).1 Prophylaxis is the...

    Source: The Lancet Haematology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetHaem
      TheLancetHaem

      "Fitusiran... provide[s] an... alternative for both haemophilia A and B... opening the door to its use in... other severe coagulation disorders" Comment @TheLancetHaem by @vjimenezyuste & @Malvarezroman #bleedingdisorders #hemophilia https://t.co/grkNtP1hEe

  • Mashup Score: 0
    Fitusiran in haemophilia: a breakthrough drug with many unknowns - 1 year(s) ago

    Haemophilia A, defined by factor VIII (FVIII) deficiency, and haemophilia B, defined by factor IX (FIX) deficiency, are X chromosome linked diseases characterised by reduced thrombin generation and bleeding symptoms.1 Prophylaxis with replacement FVIII and FIX is considered the gold standard in haemophilia treatment. Over the past two decades, the treatment landscape in haemophilia has changed…

    Source: The Lancet
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetHaem
      TheLancetHaem

      "Fitusiran might be the first prophylactic option for people with haemophilia B and perhaps an alternative approach... in people with haemophilia A" Comment @TheLancet by Flora Peyvandi, Isabella Garagiola & Maria Abbattista #bleedingdisorders #hemophilia https://t.co/ic1QgkpCt2

  • Mashup Score: 0
    Fitusiran prophylaxis in severe haemophilia without inhibitors - 1 year(s) ago

    Haemophilia is a congenital X-linked bleeding disorder caused by deficiency of coagulation factors VIII (haemophilia A) or IX (haemophilia B). Recurrent joint bleeding, leading to the development of arthropathy, is the hallmark of haemophilia and is more pronounced in people with moderate to severe forms of the disease (<1–5% of normal factor VIII or IX concentrations).1 Prophylaxis is the...

    Source: The Lancet Haematology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetHaem
      TheLancetHaem

      "Fitusiran... provide[s] an... alternative for both haemophilia A and B... opening the door to its use in... other severe coagulation disorders" Comment @TheLancetHaem by Víctor Jiménez-Yuste & María Teresa Álvarez-Román #bleedingdisorders #hemophilia https://t.co/grkNtP1hEe

  • Mashup Score: 1
    Haemophilia—unparalleled progress but inadequate access - 1 year(s) ago

    Haemophilia is an inherited bleeding disease estimated to affect 818 928 people worldwide in 2021. The condition can be life-threatening if an external bleed cannot be controlled or when there is an internal bleed to a vital organ. Internal bleeding around joints is the most common complication for patients, which can result in major disability and mobility issues, reducing patients’ quality of…

    Source: The Lancet Haematology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancetHaem
      TheLancetHaem

      "Much advocacy remains to be done to achieve treatment for all" #hemophilia #bleedingdisorders Read our new Editorial https://t.co/F8VoMFC8D9

Load More